Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.
OBJECTIVE
To review new agents under investigation for the treatment of patients with peripheral T-cell lymphoma.


RESULTS
New agents being evaluated in these patients include histone deacetylase inhibitors (e.g. romidepsin, vorinostat, and balinostat), purine analogs and agents that interfere with the purine metabolic pathway (e.g. forodesine), immunomodulatory agents, proapoptotic small molecules (e.g. oblimersen, obatoclax, and gossypol), antifols (e.g. pralatrexate), proteasome inhibitors (e.g. bortezomib), monoclonal antibodies against T-cell antigens (e.g. CD30 and CD52), and immunotoxins (e.g. denileukin diftitox).


CONCLUSIONS
The development of rational combinations of such agents in clinical trials will be required to improve the outcome of these patients.
Cheson
Bruce D
BD
Georgetown University Hospital, 3800 Reservoir Road, N.W., Washington, DC 20007, USA. bdc4@georgetown.edu
D000970:Antineoplastic Agents / Q000145:classification / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D017338:Cladribine / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000473:pathology; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001897:Boronic Acids; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D009588:Nitrogen Mustard Compounds; D011719:Pyrazines; D017338:Cladribine; D000069286:Bortezomib; D000069461:Bendamustine Hydrochloride; D014740:Vidarabine; C024352:fludarabine